More Zelira Therapeutics Ltd. news
Zelira Therapeutics Ltd.ASX: ZLD

Aus Patent For Novel Prognostic Marker for Breast Cancer

Mar 5, 2019 at 10:46 PM EST · Issued by Zelira Therapeutics Ltd.

Filed with ASX · Mar 5, 2019 at 10:46 PM EST

On 6ix: 6ix.com/news/aus-patent-for-novel-prognostic-marker-for-breast-cancer

Zelira Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Zelira Therapeutics Ltd. on 6ix

Story so far

  • Expansion of Breast Cancer Research CollaborationJul 31, 2017
  • Positive Results From Pre-Clinical Breast Cancer StudiesJun 2, 2017

Earlier from Zelira Therapeutics

  • Appendix 4D & FY19 Interim Financial ReportFeb 22, 2019
  • December 2018 Quarterly Report and Board TransitionJan 30, 2019
  • ZLD to Invest in Development of Oral Spray FormulationsDec 5, 2018
  • Opioid reduction clinical trial with St Vincents HospitalNov 25, 2018
  • September 2018 Quarterly ReportOct 31, 2018

Later from Zelira Therapeutics

  • Zelda Partners with Ilera HealthCareMar 11, 2019
  • March 2019 Quarterly ReportApr 29, 2019
  • Zelda Granted Approval for Opioid Reduction TrialJul 1, 2019
  • Response to ASX Price and Volume QueryJul 11, 2019
  • Zelda Collaborates with Emerald ClinicsJul 18, 2019
All Zelira Therapeutics news releases↗

Follow Zelira Therapeutics into a list and get an email when it puts out news.

Follow Zelira Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer